F16.14
Hallucinogen abuse with hallucinogen-induced mood disorder
Clinical Classification Guidelines
Inclusion Terms
- Other hallucinogen use disorder, mild, with other hallucinogen induced bipolar or related disorder
- Other hallucinogen use disorder, mild, with other hallucinogen induced depressive disorder
- Phencyclidine use disorder, mild, with phencyclidine induced bipolar or related disorder
- Phencyclidine use disorder, mild, with phencyclidine induced depressive disorder
Medical Intelligence & Overview
ICD-10 code F16.14 describes a condition where an individual abuses hallucinogens and experiences mood disturbances directly related to their substance use. This situation often involves mild hallucinogen use disorder coupled with mood episodes such as depression or bipolar-like symptoms induced by the drugs. Recognizing this pattern is key to understanding the complex effects of hallucinogens on mental health and the importance of proper diagnosis and treatment.
Causes & Symptoms
Clinical Causes: Recurrent use of hallucinogenic substances, including LSD, psilocybin, or PCP, which can lead to habituation or misuse. Using hallucinogens to alter mood or escape from emotional distress. Genetic predisposition or underlying mental health vulnerabilities that may increase susceptibility to substance-induced mood disorders. Environmental factors such as stress, peer influence, or co-occurring mental health conditions that contribute to substance misuse. Repeated exposure to hallucinogens, which can modify brain chemistry and disrupt normal mood regulation.
Key Symptoms: Altered perceptions and hallucinations, often visual or auditory. Mood disturbances such as depression, characterized by feelings of sadness, hopelessness, or loss of interest. Manic or hypomanic episodes resembling bipolar disorder, involving elevated mood, increased activity, or irritability. Impulsive or risky behaviors during intoxication or mood episodes. Cognitive changes like confusion, difficulty concentrating, or memory issues. Physical signs such as dilated pupils, increased heart rate, or dizziness during drug use.
Diagnostic & Treatment
Diagnosis Path: Diagnosis is based on clinical evaluation, including detailed history of substance use and symptoms. Healthcare professionals assess the pattern of hallucinogen use and related mood episodes, ruling out primary mood disorders. Laboratory tests may support diagnosis by detecting recent hallucinogen use. Mental health assessments help distinguish between substance-induced mood issues and primary mental health conditions.
Treatment Protocols: Treatment approaches typically involve a combination of approaches, including:
Clinical Advice & FAQs
Billing Guidance
Is F16.14 a billable ICD-10 code?
Yes, F16.14 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F16.14?
Clinical documentation must specify the nature of Hallucinogen abuse with hallucinogen-induced mood disorder and any associated comorbidities for accurate reporting.
Cite this Clinical Reference